SINTX acquires SiNAPTIC Surgical assets for $750K in stock plus warrants; enters foot/ankle fusion market

Sintx Technologies, Inc.

Acquired all IP and designs for six foot/ankle implant systems; market valued at $750M growing to $1.38B by 2032.
Consideration: $750K in common shares at $3.465 (10% premium) plus 325,000 performance-based warrants exercisable at $6.30.
Warrants vest upon FDA clearance and cumulative revenue milestones up to $15M; also 5% royalty after $15M.
Key SiNAPTIC executives join SINTX: Dr. Bryan Scheer leads Clinical Advisory Board, plus others in commercial and regulatory roles.
Expected closing July 1, 2025; SINTX will manufacture under its existing FDA-registered and ISO-certified quality system.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.